TxCell’s novel CAR-modified regulatory T-cell (CAR Treg) platform continues to develop well. TxCell has four indications in preclinical development with the first ever CAR Treg trial, in transplant rejection, anticipated by TxCell to start by late 2018. This could provide powerful clinical proof-of-concept data by 2020. In 2017, an €11.1m gross rights issue provided funding for 2017 with an operational cash use of €13m guided by management. In 2018, warrants could bring a furt
14 Mar 2017
Aiming for first CAR Treg
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Aiming for first CAR Treg
Txcell (TXCL:EPA) | 0 0 -1.3% | Mkt Cap: 29.4m
- Published:
14 Mar 2017 -
Author:
Dr John Savin -
Pages:
3
TxCell’s novel CAR-modified regulatory T-cell (CAR Treg) platform continues to develop well. TxCell has four indications in preclinical development with the first ever CAR Treg trial, in transplant rejection, anticipated by TxCell to start by late 2018. This could provide powerful clinical proof-of-concept data by 2020. In 2017, an €11.1m gross rights issue provided funding for 2017 with an operational cash use of €13m guided by management. In 2018, warrants could bring a furt